Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
CLNN
$5.0716
$
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Next Earnings
2026-02-25
Beta
0.679
Average Volume
Market Cap
Last Dividend
CIK
0001822791
ISIN
US1856342019
CUSIP
185634102
CEO
Robert Etherington
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
75
IPO Date
2018-10-18
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts | SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today issued a letter to stockholders outlining key anticipated regulatory and clinical milestones for CNM-Au8® in 2026. | GlobeNewsWire | 2026-02-24 08:00:00 |
| Contrasting Ventyx Biosciences (NASDAQ:VTYX) & Clene (NASDAQ:CLNN) | Ventyx Biosciences (NASDAQ: VTYX - Get Free Report) and Clene (NASDAQ: CLNN - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings. Analyst Recommendations This is a breakdown of recent | Defense World | 2026-02-22 02:05:06 |
| Clene Inc. (NASDAQ:CLNN) Receives $32.60 Consensus Target Price from Analysts | Clene Inc. (NASDAQ: CLNN - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average twelve-month price target among | Defense World | 2026-02-20 01:57:02 |
| Clene to Present at the Emerging Growth Conference | SALT LAKE CITY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference. | GlobeNewsWire | 2026-02-19 08:30:00 |
| Brokerages Set Clene Inc. (NASDAQ:CLNN) PT at $32.60 | Shares of Clene Inc. (NASDAQ: CLNN - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 1-year price target | Defense World | 2026-01-26 01:18:49 |
| Clene Conference: FDA Grants Type C Meeting as CLNN Eyes ALS CNM-Au8 Accelerated Approval in Q2 | Clene (NASDAQ: CLNN) executives told investors the clinical-stage biopharmaceutical company has secured an in-person meeting with the U.S. Food and Drug Administration (FDA) later this quarter as it continues to pursue an accelerated approval pathway for its lead program in amyotrophic lateral sclerosis (ALS). FDA meeting granted after multiple recent interactions CEO and President Rob Etherington | Defense World | 2026-01-23 01:03:02 |
| Insider Selling: Clene (NASDAQ:CLNN) Major Shareholder Sells $100,459.52 in Stock | Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 19,621 shares of the company's stock in a transaction that occurred on Wednesday, January 14th. The stock was sold at an average price of $5.12, for a total value of $100,459.52. Following the transaction, the insider owned 662,861 shares of the company's stock, | Defense World | 2026-01-19 04:44:53 |
| Clene (NASDAQ:CLNN) Major Shareholder Sells $64,071.30 in Stock | Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 12,563 shares of the firm's stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $5.10, for a total value of $64,071.30. Following the completion of the sale, the insider directly owned 650,298 shares | Defense World | 2026-01-19 04:44:51 |
| Chidozie Ugwumba Sells 26,105 Shares of Clene (NASDAQ:CLNN) Stock | Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 26,105 shares of Clene stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $4.89, for a total value of $127,653.45. Following the completion of the transaction, the insider owned 682,482 shares of the company's stock, | Defense World | 2026-01-18 05:40:54 |
| Clene to Present at the Emerging Growth Conference | SALT LAKE CITY, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference. | GlobeNewsWire | 2026-01-16 08:30:00 |
| David Matlin Buys 33,333 Shares of Clene (NASDAQ:CLNN) Stock | Clene Inc. (NASDAQ: CLNN - Get Free Report) Director David Matlin acquired 33,333 shares of the business's stock in a transaction on Tuesday, January 13th. The stock was acquired at an average price of $6.50 per share, with a total value of $216,664.50. Following the transaction, the director owned 477,824 shares in the company, valued at | Defense World | 2026-01-15 04:44:59 |
| Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting | SALT LAKE CITY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that the U.S. Food and Drug Administration (FDA) has granted Clene an in-person Type C Meeting later this quarter. | GlobeNewsWire | 2026-01-12 08:30:00 |
| Clene Announces Registered Direct Offering of Over $28 Million | Oversubscribed registered direct offering priced above market to new, existing and insider investors, including Boxer Capital Management, Coastlands Capital, and Vivo Capital Initial financing tranche of over $6 million, which we expect will provide cash runway into the third quarter of 2026 enabling funding through potential NDA acceptance decision by the FDA, with two additional financing tranches totaling over $22 million contingent on NDA acceptance and NDA approval by the FDA Completion of this financing through its three tranches is expected to provide the Company with sufficient capital into early 2027, which we expect will allow potential commercialization of CNM-Au8 in ALS SALT LAKE CITY, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary, Clene Nanomedicine, Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced a registered direct offering priced above market under Nasdaq rules of over $28 million by new and existing investors. “We are happy to welcome top-tier investors Boxer Capital, Coastlands Capital and Vivo Capital, along with other current insider investors, who share our excitement and enthusiasm for the important work that Clene has undertaken in ALS,” said Rob Etherington, CEO of Clene, Inc. “Their investment further validates the promise and potential of ALS biomarkers and survival data for a planned New Drug Application in ALS in 2026 for CNM-Au8, on which Clene has been focused. | GlobeNewsWire | 2026-01-09 08:30:00 |
| Insider Selling: Clene (NASDAQ:CLNN) Major Shareholder Sells $24,952.14 in Stock | Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 4,138 shares of the stock in a transaction dated Tuesday, December 30th. The stock was sold at an average price of $6.03, for a total transaction of $24,952.14. Following the completion of the transaction, the insider directly owned 783,590 shares of the company's | Defense World | 2026-01-03 05:12:42 |
| Chidozie Ugwumba Sells 8,096 Shares of Clene (NASDAQ:CLNN) Stock | Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 8,096 shares of the business's stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $5.95, for a total value of $48,171.20. Following the sale, the insider directly owned 787,728 shares of the company's | Defense World | 2026-01-02 05:10:56 |
| Clene (NASDAQ:CLNN) Major Shareholder Sells $42,830.37 in Stock | Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 6,831 shares of Clene stock in a transaction on Tuesday, December 23rd. The shares were sold at an average price of $6.27, for a total value of $42,830.37. Following the completion of the transaction, the insider owned 800,664 shares of the company's stock, | Defense World | 2026-01-02 05:10:54 |
| Clene Inc. (NASDAQ:CLNN) Given Consensus Rating of “Moderate Buy” by Analysts | Clene Inc. (NASDAQ: CLNN - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven ratings firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 1-year target price | Defense World | 2025-12-29 05:45:14 |
| Clene (NASDAQ:CLNN) Major Shareholder Sells $444,695.22 in Stock | Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 56,577 shares of the business's stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $7.86, for a total value of $444,695.22. Following the completion of the sale, the insider owned 594,368 shares of | Defense World | 2025-12-21 06:06:43 |
| Clene to Present at the Emerging Growth Conference | SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference. | GlobeNewsWire | 2025-12-09 08:30:00 |
| Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream | MIAMI, Dec. 09, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth. com a leading independent small cap media portal announces the schedule of the 88th Emerging Growth Conference on December 10 and 11, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products and services, focused strategy, execution, and the overall potential for long-term growth. | Globe News Wire | 2025-12-09 08:10:01 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 8-K | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-20 | 2026-02-20 | View Filing |
| 4 | 2026-02-20 | 2026-02-20 | View Filing |
| 4 | 2026-02-20 | 2026-02-20 | View Filing |
| 4 | 2026-02-20 | 2026-02-20 | View Filing |
| 4 | 2026-02-20 | 2026-02-20 | View Filing |
| 4 | 2026-02-20 | 2026-02-20 | View Filing |
| 4 | 2026-02-20 | 2026-02-20 | View Filing |
| 4 | 2026-02-20 | 2026-02-20 | View Filing |
| 4 | 2026-02-05 | 2026-02-05 | View Filing |
| 4 | 2026-02-02 | 2026-02-02 | View Filing |
| 4 | 2026-01-28 | 2026-01-28 | View Filing |
| 4 | 2026-01-23 | 2026-01-23 | View Filing |
| 4 | 2026-01-23 | 2026-01-23 | View Filing |
| 4 | 2026-01-23 | 2026-01-23 | View Filing |
| 4 | 2026-01-23 | 2026-01-23 | View Filing |
| 4 | 2026-01-21 | 2026-01-21 | View Filing |
| 4 | 2026-01-16 | 2026-01-16 | View Filing |
| 4 | 2026-01-13 | 2026-01-13 | View Filing |
| 8-K | 2026-01-13 | 2026-01-13 | View Filing |
| 4 | 2026-01-13 | 2026-01-13 | View Filing |
| 4 | 2026-01-12 | 2026-01-12 | View Filing |
| 8-K | 2026-01-12 | 2026-01-12 | View Filing |
| 424B5 | 2026-01-09 | 2026-01-09 | View Filing |
| 4 | 2026-01-07 | 2026-01-07 | View Filing |
| 4 | 2026-01-02 | 2026-01-02 | View Filing |
| 4 | 2025-12-31 | 2025-12-31 | View Filing |
| 4 | 2025-12-30 | 2025-12-30 | View Filing |
| 25-NSE | 2025-12-30 | 2025-12-29 | View Filing |
| 4 | 2025-12-23 | 2025-12-23 | View Filing |
| 4 | 2025-12-18 | 2025-12-18 | View Filing |
| 8-K | 2025-12-03 | 2025-12-03 | View Filing |
| 8-K | 2025-12-03 | 2025-12-03 | View Filing |
| 4 | 2025-11-14 | 2025-11-14 | View Filing |
| 4 | 2025-11-14 | 2025-11-14 | View Filing |
| 4 | 2025-11-14 | 2025-11-14 | View Filing |
| 4 | 2025-11-14 | 2025-11-14 | View Filing |
| 4 | 2025-11-14 | 2025-11-14 | View Filing |
| 4 | 2025-11-14 | 2025-11-14 | View Filing |
| 4 | 2025-11-14 | 2025-11-14 | View Filing |
| 4 | 2025-11-14 | 2025-11-14 | View Filing |
| SC 13G/A | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-11-13 | 2025-11-13 | View Filing |
| 10-Q | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-10-17 | 2025-10-17 | View Filing |
| 424B5 | 2025-10-17 | 2025-10-17 | View Filing |
| 8-K | 2025-10-14 | 2025-10-14 | View Filing |
| 4/A | 2025-09-30 | 2025-09-30 | View Filing |
| 4/A | 2025-09-30 | 2025-09-30 | View Filing |
| 4/A | 2025-09-30 | 2025-09-30 | View Filing |
| 4 | 2025-09-29 | 2025-09-29 | View Filing |
| 4 | 2025-09-29 | 2025-09-29 | View Filing |
| 4 | 2025-09-29 | 2025-09-29 | View Filing |
| 8-K | 2025-09-25 | 2025-09-25 | View Filing |
| 4 | 2025-09-19 | 2025-09-19 | View Filing |
| 4 | 2025-09-19 | 2025-09-19 | View Filing |
| 4 | 2025-09-19 | 2025-09-19 | View Filing |
| EFFECT | 2025-09-15 | 2025-09-15 | View Filing |
| 424B3 | 2025-09-12 | 2025-09-12 | View Filing |
| 8-K | 2025-09-05 | 2025-09-05 | View Filing |
| 424B5 | 2025-09-05 | 2025-09-05 | View Filing |
| S-3 | 2025-09-05 | 2025-09-05 | View Filing |
| S-8 | 2025-09-05 | 2025-09-05 | View Filing |
| 4 | 2025-08-21 | 2025-08-21 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| 8-K | 2025-08-14 | 2025-08-14 | View Filing |
| 10-Q | 2025-08-14 | 2025-08-14 | View Filing |
| 8-K | 2025-07-03 | 2025-07-03 | View Filing |
| 424B5 | 2025-07-03 | 2025-07-03 | View Filing |
| 8-K | 2025-06-30 | 2025-06-30 | View Filing |
| 8-K | 2025-06-17 | 2025-06-17 | View Filing |
| 4 | 2025-06-04 | 2025-06-04 | View Filing |
| 4 | 2025-06-02 | 2025-06-02 | View Filing |
| 4 | 2025-05-30 | 2025-05-30 | View Filing |
| 4 | 2025-05-29 | 2025-05-29 | View Filing |
| 4 | 2025-05-28 | 2025-05-28 | View Filing |
| 4 | 2025-05-27 | 2025-05-27 | View Filing |
| 8-K | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| SD | 2025-05-16 | 2025-05-16 | View Filing |
| 10-Q | 2025-05-07 | 2025-05-07 | View Filing |
| 8-K | 2025-05-07 | 2025-05-07 | View Filing |
| 424B5 | 2025-04-28 | 2025-04-28 | View Filing |
| 8-K | 2025-04-28 | 2025-04-28 | View Filing |
| EFFECT | 2025-04-28 | 2025-04-28 | View Filing |
| ARS | 2025-04-08 | 2025-04-08 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Turtle Trading Strategy | 69.11% | 1.02 | 136 | 0.05 | 0.13 | 71.69 |
| Larry Williams PercentR Strategy | 61.19% | 0.99 | 180 | 0.04 | 0.09 | 63.78 |
| Fractal Pattern | 52.54% | 0.99 | 74 | 0.04 | 0.09 | 55.12 |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxx | xxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | x | x | x |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | x | x | x |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |